Ovarian Hyperstimulation Syndrome (OHSS)

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Hyperstimulation Syndrome

MalaCards integrated aliases for Ovarian Hyperstimulation Syndrome:

Name: Ovarian Hyperstimulation Syndrome 57 12 59 74 37 29 13 55 6 44 15 40 72
Ohss 57 59 74
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous 57
Secondary Meig's Syndrome 12



autosomal dominant

symptoms occur only during pregnancy (usual onset after 6 weeks gestation)
major fluid shifts may occur in severe cases


ovarian hyperstimulation syndrome:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:5425
OMIM 57 608115
KEGG 37 H01039
MeSH 44 D016471
MESH via Orphanet 45 D016471
ICD10 via Orphanet 34 N98.1
UMLS via Orphanet 73 C0085083
Orphanet 59 ORPHA64739
MedGen 42 C0085083
UMLS 72 C0085083

Summaries for Ovarian Hyperstimulation Syndrome

KEGG : 37
Ovarian hyperstimulation syndrome (OHSS) is typically an iatrogenic complication of ovulation induction (OI) occurring during the luteal phase or early pregnancy. OHSS is characterised by a cystic enlargement of the ovaries and an acute fluid shift from the intravascular to the third space, which may result in ascites, pleural infusions, pericardial infusion, and even generalized edema. Majority of OHSS cases have been associated with the use of gonadotrophins for OI in anovulatory women or for ovarian stimulation (OS) in the context of assisted reproductive technology (ART). Recurrent cases and familial occurrence of OHSS have been described, and different mutations in the follicle-stimulating hormone receptor (FSHr) have been reported in these cases. Polycystic ovarian syndrome (PCOS) appears to be the major predisposing factor for OHSS in a large number of studies.

MalaCards based summary : Ovarian Hyperstimulation Syndrome, also known as ohss, is related to ectopic pregnancy and polycystic ovary syndrome, and has symptoms including vomiting, abdominal pain and nausea. An important gene associated with Ovarian Hyperstimulation Syndrome is FSHR (Follicle Stimulating Hormone Receptor), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Integrin Pathway. The drugs Aspirin and Cetrorelix have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and pituitary, and related phenotypes are ascites and abdominal pain

Disease Ontology : 12 An ovarian disease that is characterized by cystic enlargement of the ovaries and a fluid shift from the intravascular to the third space and has symptom abdominal pain, has symptom nausea and has symptom vomiting. This disease is an iatrogenic complication of assisted reproduction technology.

UniProtKB/Swiss-Prot : 74 Ovarian hyperstimulation syndrome: Disorder which occurs either spontaneously or most often as an iatrogenic complication of ovarian stimulation treatments for in vitro fertilization. The clinical manifestations vary from abdominal distention and discomfort to potentially life-threatening, massive ovarian enlargement and capillary leak with fluid sequestration. Pathologic features of this syndrome include the presence of multiple serous and hemorrhagic follicular cysts lined by luteinized cells, a condition called hyperreactio luteinalis.

Wikipedia : 75 Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who take... more...

More information from OMIM: 608115

Related Diseases for Ovarian Hyperstimulation Syndrome

Diseases related to Ovarian Hyperstimulation Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 ectopic pregnancy 31.5 VEGFA GNRH1 CGA
2 polycystic ovary syndrome 31.3 GNRH1 FSHR CYP19A1
3 estrogen excess 30.5 FSHR CYP19A1
4 endometriosis 30.5 VEGFA GNRH1 CYP19A1
5 retinal artery occlusion 30.5 VEGFA F5
6 central retinal vein occlusion 30.4 VEGFA F5
7 luteoma 30.3 CYP19A1 CGA
8 anuria 30.3 REN ALB
9 hypogonadism 30.2 LHCGR GNRH1 FSHB
10 amenorrhea 30.2 LHCGR GNRH1 FSHR FSHB
11 infertility 30.0 LHCGR GNRH1 FSHR FSHB CYP19A1
12 precocious puberty 29.8 LHCGR GNRH1 CYP19A1
13 vascular disease 29.6 VEGFA REN F5 ALB
14 anovulation 29.6 GNRH1 FSHR FSHB CYP19A1 CGA
15 pre-eclampsia 29.5 VEGFA REN KDR F5
16 myocardial infarction 29.2 VEGFA REN F5 CDH5 ALB
17 ovarian disease 27.7 VEGFA REN LHCGR GNRH1 FSHR CYP19A1
18 capillary leak syndrome 11.8
19 thrombosis 10.7
20 hypothyroidism 10.7
21 ovarian cyst 10.6
22 thrombophilia due to thrombin defect 10.6
23 severe nonproliferative diabetic retinopathy 10.6 VEGFA ALB
24 hypogonadotropic hypogonadism 23 without anosmia 10.6 GNRH1 FSHR
25 acroosteolysis 10.5 VEGFA ALB
26 angiokeratoma circumscriptum 10.5 VEGFA KDR
27 adenoma 10.5
28 adult respiratory distress syndrome 10.5
29 background diabetic retinopathy 10.5 VEGFA ALB
30 leydig cell hypoplasia 10.5 LHCGR CGA
31 hydrocele 10.5 VEGFA CGA
32 radiation proctitis 10.5 VEGFA KDR
33 hypertensive nephropathy 10.5 VEGFA ALB
34 skin hemangioma 10.5 VEGFA KDR
35 hydrops, lactic acidosis, and sideroblastic anemia 10.5
36 hemopericardium 10.5
37 pericardial effusion 10.5
38 thrombophilia 10.5
39 epithelioid hemangioendothelioma 10.5 VEGFA KDR
40 nodular prostate 10.5 KDR GNRH1
41 ischemic colitis 10.5 VEGFA F5
42 pituitary adenoma 10.5
43 capillary hemangioma 10.5 VEGFA KDR
44 gastric lymphoma 10.4 VEGFA ALB
45 respiratory failure 10.4
46 compartment syndrome 10.4
47 pulmonary embolism 10.4
48 retinal vascular occlusion 10.4 VEGFA F5
49 benign essential hypertension 10.4 REN ALB
50 angiomatous meningioma 10.4 VEGFA KDR

Graphical network of the top 20 diseases related to Ovarian Hyperstimulation Syndrome:

Diseases related to Ovarian Hyperstimulation Syndrome

Symptoms & Phenotypes for Ovarian Hyperstimulation Syndrome

Human phenotypes related to Ovarian Hyperstimulation Syndrome:

59 32 (show all 18)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 59 32 hallmark (90%) Very frequent (99-80%) HP:0001541
2 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
3 increased circulating gonadotropin level 59 32 hallmark (90%) Very frequent (99-80%) HP:0000837
4 enlarged polycystic ovaries 59 32 hallmark (90%) Very frequent (99-80%) HP:0008675
5 abdominal distention 59 32 hallmark (90%) Very frequent (99-80%) HP:0003270
6 increased serum testosterone level 59 32 hallmark (90%) Very frequent (99-80%) HP:0030088
7 nausea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002018
8 hirsutism 59 32 hallmark (90%) Very frequent (99-80%) HP:0001007
9 capillary leak 59 32 hallmark (90%) Very frequent (99-80%) HP:0030005
10 pleural effusion 59 32 frequent (33%) Frequent (79-30%) HP:0002202
11 hemorrhagic ovarian cyst 59 32 frequent (33%) Frequent (79-30%) HP:0012886
12 hypovolemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011106
13 peripheral edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0012398
14 generalized edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0007430
15 pulmonary edema 59 32 occasional (7.5%) Occasional (29-5%) HP:0100598
16 nausea and vomiting 59 Very frequent (99-80%)
17 abnormality of the genitourinary system 32 HP:0000119
18 ovarian cyst 59 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM:

abdominal pain

Genitourinary Internal Genitalia Female:
enlarged multilocular ovaries
pathology shows multiple serous and hemorrhagic follicular cysts lined by luteinized cells ('hyperreactio luteinalis')
ovaries return to normal size after delivery

Abdomen Gastrointestinal:

Clinical features from OMIM:



  • vomiting
  • abdominal pain
  • nausea

UMLS symptoms related to Ovarian Hyperstimulation Syndrome:

abdominal pain, nausea

MGI Mouse Phenotypes related to Ovarian Hyperstimulation Syndrome:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.27 ALB AMH CDH5 CGA CYP19A1 F5
2 endocrine/exocrine gland MP:0005379 10.21 ALB AMH CDH5 CGA CYP19A1 FSHB
3 growth/size/body region MP:0005378 10.19 CDH5 CGA CYP19A1 F5 FSHR GNRH1
4 cardiovascular system MP:0005385 10.14 CDH5 CYP19A1 F5 FSHR KDR LHCGR
5 cellular MP:0005384 10.13 ALB CDH5 CYP19A1 FSHB FSHR KDR
6 hematopoietic system MP:0005397 10.08 CDH5 CYP19A1 FSHR GNRH1 KDR LHCGR
7 immune system MP:0005387 10.03 CDH5 CYP19A1 FSHR GNRH1 KDR LHCGR
8 liver/biliary system MP:0005370 9.97 ALB CDH5 CYP19A1 F5 GNRH1 KDR
9 integument MP:0010771 9.95 CDH5 CYP19A1 F5 FSHR GNRH1 KDR
10 nervous system MP:0003631 9.91 CGA CYP19A1 F5 FSHR GNRH1 KDR
11 neoplasm MP:0002006 9.72 ALB AMH FSHR GNRH1 VEGFA
12 normal MP:0002873 9.7 ALB CDH5 CYP19A1 GNRH1 KDR REN
13 renal/urinary system MP:0005367 9.43 ALB CYP19A1 GNRH1 LHCGR REN VEGFA
14 reproductive system MP:0005389 9.32 AMH CDH5 CGA CYP19A1 FSHB FSHR

Drugs & Therapeutics for Ovarian Hyperstimulation Syndrome

Drugs for Ovarian Hyperstimulation Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
Cabergoline Approved Phase 4 81409-90-7 54746
Ganirelix Approved Phase 4 124904-93-4, 123246-29-7 25081094
Nafarelin Approved Phase 4 76932-56-4 16129618 25077649
Menotropins Approved Phase 4 61489-71-2, 9002-68-0 5360545
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
leucovorin Approved Phase 4 58-05-9 143 6006
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
Buserelin Approved, Investigational Phase 4 57982-77-1
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
14 Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
15 Progestins Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4
18 Protective Agents Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Platelet Aggregation Inhibitors Phase 4
21 Antirheumatic Agents Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Fibrinolytic Agents Phase 4
24 Antipyretics Phase 4
25 Neurotransmitter Agents Phase 4
26 Dopamine Agents Phase 4
27 Dopamine agonists Phase 4
28 Antiparkinson Agents Phase 4
29 Triptorelin Pamoate Phase 4
30 Contraceptive Agents Phase 4
31 Autonomic Agents Phase 4
32 Sympathomimetics Phase 4
33 Cardiotonic Agents Phase 4
34 Hypoglycemic Agents Phase 4
35 Alpha-lipoic Acid Phase 4
36 cysteine Phase 4
37 Thioctic Acid Phase 4
38 Steroid Synthesis Inhibitors Phase 4
39 Estrogen Receptor Antagonists Phase 4
40 Estrogen Antagonists Phase 4
41 Aromatase Inhibitors Phase 4
42 Micronutrients Phase 4
43 Trace Elements Phase 4
44 Vitamins Phase 4
45 Nutrients Phase 4
46 Prolactin Release-Inhibiting Factors Phase 4
47 Fertility Agents Phase 4
48 Chorionic Gonadotropin Phase 4
49 Luteolytic Agents Phase 4
50 Antineoplastic Agents, Hormonal Phase 4

Interventional clinical trials:

(show top 50) (show all 207)
# Name Status NCT ID Phase Drugs
1 Preventive Application of GnRH Antagonist on Early Ovarian Hyperstimulation Syndrome in High-risk Women: A Prospective Randomized Trial Unknown status NCT03188471 Phase 4 GnRH antagonist;aspirin
2 Randomized Controlled Trial Comparing the Effect of GnRH Agonist and Antagonist Ovarian Stimulation Protocols in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
3 A Prospective Randomized Study Comparing Coasting by Withholding GnRH Agonist With GnRH Antagonist Administration in Patients at Risk for Severe OHSS Unknown status NCT01347268 Phase 4
4 Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study Unknown status NCT02215135 Phase 4 Corifollitropin alfa
5 Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients Unknown status NCT00415792 Phase 4 Arvekap, Pregnyl
6 Corifollitropin Alfa (Elonva) Versus Follitropin Beta in High Responders: A Randomized Controlled Trial Unknown status NCT02471677 Phase 4 Elonva;Puregon
7 A Comparison Study of a Novel Stimulation Protocol With Metformin in Step-down Regimen and the Conventional Low Dose Step-up Protocol in Patients With Polycystic Ovary Syndrome Undergoing in Vitro Fertilization Unknown status NCT01438190 Phase 4 Metformin, gonadotropins in step-down regimen;Placebo, gonadotropins in step-up regimen
8 PERCING : Ovarian Drilling Versus Ovarian Stimulation + Intra Uterine Insemination (IUI) + Metformin in the PCOS (PolyCystic Ovaries Syndrome) Treatment Unknown status NCT00378729 Phase 4 Metformin and FSHr
9 Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer Unknown status NCT03309436 Phase 4 Clomiphene Citrate protocol
10 Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial Unknown status NCT02703649 Phase 4 Letrozole
11 Prospective Randomized Trial on GnRH Agonist Triggering Versus hCG Triggering in IVF Stimulation in PCOS Patients Unknown status NCT01683513 Phase 4 GnRh agonist +1500E hCG
12 A Phase IV Study on the Effect of Luteal Supplementation With Rec-LH on the Pregnancy Rate After Ovulation Triggering With GnRH-agonist Instead of HCG in IVF Protocol;Proof of Concept Unknown status NCT00954811 Phase 4 300IU rec-LH;progesterone 600mg
13 Endometrial Receptivity After GnRH Agonist Triggering From Final Oocyte Maturation Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
14 Endometrial Advancement After Rec or u-HCG Triggering Completed NCT00953628 Phase 4 10000 IU urinary HCG;250 mcg recombinant HCG
15 A Prospective Randomized Study Comparing the Use of hCG or GnRH Agonist to Trigger Final Oocyte Maturation in High Responders Undergoing in-Vitro Fertilization Treatment Completed NCT00349258 Phase 4 Leuprolide acetate
16 A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl) Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
17 A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
18 Short Versus Long IVF-treatment. A Prospective, Consecutive and Randomized Comparative Study Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
19 The Randomized Controlled Trial Study of Letrozole in the Prevention of Medium and Severe Ovarian Hyperstimulation Syndrome in Invitro Fertilization Treatment Completed NCT02670304 Phase 4 letrozole;Aspirin
20 The Influence of Dopamine Agonist Cabergoline on Oocyte Maturation in Women Undergoing Assisted Reproduction Completed NCT01065376 Phase 4
21 Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization Completed NCT01233206 Phase 4 Metformin;Placebo administration
22 Randomised Clinical Trial Comparing Highly Purified FSH Formulation (Fostimon®) and Recombinant FSH (Gonal-F®) in GnRH-antagonist Controlled Ovarian Hyperstimulation Cycles. Completed NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
23 A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II) Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
24 Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG Completed NCT01638026 Phase 4 TRIPTORELIN ACETATE, hCG
25 An Efficacy and Safety Study of Corifollitropin Alfa Versus Daily Follitropin Beta for Controlled Ovarian Stimulation in Women 35-42 Years Old With a Body Weight ≥ 50 kg Undergoing IVF Treatment. Completed NCT02466204 Phase 4 corifollitropin alfa;Follitropin Beta
26 Synchronization of Follicle Wave Emergence and Ovarian Stimulation in Women With a History of Poor Ovarian Response to Treatment Completed NCT00439829 Phase 4 Gonal F;Luveris;Cetrotide;hCG
27 GnRH Agonist and Antagonists in an Oocyte Donation Program Completed NCT00505817 Phase 4 Cetrorelix and Leuprolide
28 Analysis of Follicular Steroid Synthesis During Controlled Ovarian Stimulation With Recombinant FSH vs HMG in GnRH Antagonist Cycles Completed NCT02738580 Phase 4 COS with GnRH antagonists and rFSH;COS with GnRH antagonists and HP-HMG
29 Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders; a Randomized Controlled Trial Completed NCT03759301 Phase 4 Growth Hormones Somatropin Recombinant;Placebo saline solution
30 Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct and GnRH Agonist Trigger for Egg Bank Donation Completed NCT02069808 Phase 4 Follistim;Ganirelix;Menotropins;Leuprolide
31 Randomised Controlled Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist Completed NCT01607203 Phase 4 Decapeptyl Daily;pregnyl
32 Influence of Ovarian Stimulation With hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4 HMG;rFSH
33 Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI Completed NCT03118830 Phase 4 Triptorelin;cetrorelix;Recombinant Follicle Stimulating Hormone
34 Clinical Use of the Perifollicular Vascularity Assessment in in-Vitro Fertilization Cycles: a Pilot Study Completed NCT00458380 Phase 4
35 Coasting Versus Gonadotrophin-Releasing Hormone Antagonist Administration in Patients at High Risk of Ovarian Hyperstimulation Syndrome and Its Impact on the Embryos Quality and the Outcome of ICSI Recruiting NCT03996434 Phase 4 Gonadotropin;Antagonist
36 The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies: A Prospective Randomized Controlled Trial Recruiting NCT03169166 Phase 4 Triptorelin
37 Effect of Myo-Inositol- Based Co-treatment on Oocyte Quality in Women With Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology Recruiting NCT03177122 Phase 4 Myo-inositol
38 Dual Trigger Versus Gonadotropin Releasing Hormone Agonist Trigger Combined With Luteal Human Chorionic Gonadotropin Administration Recruiting NCT02330770 Phase 4 GnRHa and HCG;GnRHa then HCG (single low-dose);GnRHa then HCG (multiple low-doses)
39 A Randomized Controlled Trial of Pre-retrieval Triggering Methods in in Vitro Fertilization Patients Classified as Low, Normal or High Responder Recruiting NCT02715336 Phase 4 Ovulation induction with hCG and Lupron (GnRH agonist)
40 Prospective Randomised Clinical Study on Pharmacogenetics of Gonadotropin Receptors in Relation to Pregnancy and Life Birth Rate as Well as Unwanted Side Effects Such as Ovarian Hyper Stimulation Syndrome During Assisted Reproduction. Recruiting NCT03737253 Phase 4 Follitropin alpha;Menotropin
41 Does Use of Letrozole in Controlled Ovarian Stimulation in Normal Ovarian Responder in Fresh Embryo Transfer IVF/ICSI Cycle Improve the Pregnancy Rate? Not yet recruiting NCT03901170 Phase 4 Letrozole 2.5mg
42 The Effectiveness and Safety of the Early Follicular Phase Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation: a Randomized, Paralleled, Controlled, Multicenter Trial Not yet recruiting NCT03809221 Phase 4 Triptorelin acetate
43 Can Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist Withstand When Administered at Different Points in the Menstrual Cycle? Not yet recruiting NCT04060992 Phase 4 Elagolix 200 MG Oral Tablet [Orilissa]
44 Follicular Fluid, Serum Endocrine Profile Following Stimulation With Recombinant Gonadotropins or Highly Purified Human Menopausal Gonadotropin During GnRH-antagonist Protocol Not yet recruiting NCT02992808 Phase 4 recombinant gonadotropins;HP-HMG
45 Comparison of Embryo Transfer With and Without PGS for the Indication of Advanced Reproductive Age (37-42) in Patients Undergoing ART Suspended NCT00646893 Phase 4
46 An Uncontrolled, Open-label Feasibility Study to Demonstrate That a GnRH Agonist (Decapeptyl) Can be Safely Administered to Trigger Final Oocyte Maturation in High Responder Patients to Mitigate the Risk of OHSS Terminated NCT01714648 Phase 4 Triptorelin 0.2 mg
47 Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF) Terminated NCT02221154 Phase 4
48 A Prospective Comparison of Transcriptional Profiling of Luteal Phase Endometrial Biopsies After Induction of Oocyte Maturation With a Gonadotropin Releasing Hormone (GnRH) Agonist or Human Chorionic Gonadotropins (hCG) Terminated NCT01606709 Phase 4 GnRH agonist;hCG
49 A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction Terminated NCT01871532 Phase 4 Gonal-f®
50 Open Label Pilot Study on Gene Expression Profiling of the Endometrial Tissue in Patients Undergoing Assisted Reproductive Technology [ART: In Vitro Fertilization (IVF)/ Intracytoplasmic Sperm Injection (ICSI)] With GONAL-f® Terminated NCT01210144 Phase 4 Gonal -f® [r-hFSH];Ovitrelle® [r-hCG alfa];Gonadotropin-releasing hormone (GnRH) Agonist;Gonadotropin-releasing hormone (GnRH) Antagonist

Search NIH Clinical Center for Ovarian Hyperstimulation Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :

Ganirelix acetate

Cochrane evidence based reviews: ovarian hyperstimulation syndrome

Genetic Tests for Ovarian Hyperstimulation Syndrome

Genetic tests related to Ovarian Hyperstimulation Syndrome:

# Genetic test Affiliating Genes
1 Ovarian Hyperstimulation Syndrome 29 FSHR

Anatomical Context for Ovarian Hyperstimulation Syndrome

MalaCards organs/tissues related to Ovarian Hyperstimulation Syndrome:

Ovary, Endothelial, Pituitary, Breast, Liver, Testes, Bone

Publications for Ovarian Hyperstimulation Syndrome

Articles related to Ovarian Hyperstimulation Syndrome:

(show top 50) (show all 2919)
# Title Authors PMID Year
Identification of the first germline mutation in the extracellular domain of the follitropin receptor responsible for spontaneous ovarian hyperstimulation syndrome. 9 38 8 71
17721928 2008
A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. 9 38 8 71
12930927 2003
Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. 9 38 8 71
12930928 2003
Spontaneous ovarian hyperstimulation syndrome in four consecutive pregnancies. 38 8 71
8894317 1996
Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. 9 38 71
16278261 2006
A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. 9 38 71
15080154 2004
Increased concentrations of renin, aldosterone and Ca125 in a case of spontaneous, recurrent, familial, severe ovarian hyperstimulation syndrome. 9 38 71
9402264 1997
Spontaneous ovarian hyperstimulation syndrome presenting with acute abdomen. 38 8
16679690 2006
Prediction of severity of symptoms in iatrogenic ovarian hyperstimulation syndrome by follicle-stimulating hormone receptor Ser680Asn polymorphism. 38 71
15579795 2004
The pathogenesis of the ovarian hyperstimulation syndrome. 38 8
12930924 2003
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. 38 8
12498425 2002
A common single nucleotide polymorphism in exon 10 of the human follicle stimulating hormone receptor is a major determinant of length and hormonal dynamics of the menstrual cycle. 71
15886248 2005
Follicle-stimulating-hormone receptor and twinning. 71
11213123 2001
Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. 9 38
20423279 2010
Ovarian hyperstimulation syndrome (OHSS) due to mutations in the follicle-stimulating hormone receptor. 9 38
20362966 2010
Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. 9 38
19800620 2010
The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. 9 38
20139430 2010
Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro. 9 38
19342033 2010
Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. 9 38
20008399 2010
[Increased risk of early pregnancy loss and lower live birth rate with GNRH antagonist vs. long GNRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation]. 9 38
20209851 2009
GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. 9 38
19909588 2009
GnRHa to trigger final oocyte maturation: a time to reconsider. 9 38
19608565 2009
A unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats. 9 38
19443574 2009
Insights into angiogenic imbalances during pregnancy. 9 38
19622952 2009
Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? 9 38
19573290 2009
Miscarriage and clinical correlates of leukocyte count in patients with ovarian hyperstimulation syndrome. 9 38
19835500 2009
[Analysis of the clinical outcomes of IVF-ET treatment in infertile patients with polycystic ovary syndrome or polycystic ovaries]. 9 38
19460721 2009
GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study. 9 38
18692821 2009
Possible familial gestational spontaneous ovarian hyperstimulation syndrome due to mutation of FSH receptors (FGSOHS). 9 38
19391457 2009
Induction of ovulation by a potent, orally active, low molecular weight agonist (Org 43553) of the luteinizing hormone receptor. 9 38
19088107 2009
Follicle-stimulating hormone receptor polymorphism (Thr307Ala) is associated with variable ovarian response and ovarian hyperstimulation syndrome in Indian women. 9 38
18321487 2009
Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. 9 38
19192339 2009
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. 9 38
18367175 2009
In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols. 9 38
18321490 2009
High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome. 9 38
19688946 2009
Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol. 9 38
19146764 2009
Human corpus luteum physiology and the luteal-phase dysfunction associated with ovarian stimulation. 9 38
19406027 2009
The luteal phase after 3 decades of IVF: what do we know? 9 38
20034417 2009
Mutations and polymorphisms of the FSH receptor (FSHR) gene: clinical implications in female fecundity and molecular biology of FSHR protein and gene. 9 38
19017414 2008
Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. 9 38
18439601 2008
Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome. 9 38
19102964 2008
Does elevated human chorionic gonadotropin alone trigger spontaneous ovarian hyperstimulation syndrome? 9 38
18166181 2008
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. 9 38
18385260 2008
Role of human albumin in ovarian hyperstimulation syndrome. 9 38
18468600 2008
Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. 9 38
18171700 2008
Patient and nurse evaluation of recombinant human follicle-stimulating hormone administration methods: comparison of two follitropin injection pens. 9 38
18230195 2008
Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization. 9 38
18400585 2008
Spontaneous ovarian hyperstimulation in a naturally conceived pregnancy with uncontrolled hypothyroidism. 9 38
18238999 2008
Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)? 9 38
18164141 2008
Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome. 9 38
18159088 2008

Variations for Ovarian Hyperstimulation Syndrome

ClinVar genetic disease variations for Ovarian Hyperstimulation Syndrome:

6 (show all 31)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 FSHR NM_000145.3(FSHR): c.1346C> T (p.Thr449Ile) single nucleotide variant Pathogenic rs28928870 2:49190614-49190614 2:48963475-48963475
2 FSHR NM_000145.3(FSHR): c.1699G> A (p.Asp567Asn) single nucleotide variant Pathogenic rs28928871 2:49190261-49190261 2:48963122-48963122
3 FSHR NM_000145.3(FSHR): c.1345A> G (p.Thr449Ala) single nucleotide variant Pathogenic rs121909663 2:49190615-49190615 2:48963476-48963476
4 FSHR NM_000145.3(FSHR): c.1634T> C (p.Ile545Thr) single nucleotide variant Pathogenic rs121909664 2:49190326-49190326 2:48963187-48963187
5 FSHR NM_000145.3(FSHR): c.383C> A (p.Ser128Tyr) single nucleotide variant Pathogenic rs121909665 2:49217768-49217768 2:48990629-48990629
6 FSHR NM_000145.3(FSHR): c.1576T> C (p.Leu526=) single nucleotide variant Uncertain significance rs138281715 2:49190384-49190384 2:48963245-48963245
7 FSHR NM_000145.3(FSHR): c.373C> A (p.Leu125Met) single nucleotide variant Uncertain significance rs886056151 2:49244629-49244629 2:49017490-49017490
8 FSHR NM_000145.3(FSHR): c.*199A> G single nucleotide variant Uncertain significance rs886056148 2:49189673-49189673 2:48962534-48962534
9 FSHR NM_000145.3(FSHR): c.1831C> G (p.Leu611Val) single nucleotide variant Uncertain significance rs886056149 2:49190129-49190129 2:48962990-48962990
10 FSHR NM_000145.3(FSHR): c.688A> G (p.Ile230Val) single nucleotide variant Uncertain significance rs367711694 2:49196003-49196003 2:48968864-48968864
11 FSHR NM_000145.3(FSHR): c.219G> A (p.Glu73=) single nucleotide variant Uncertain significance rs377397067 2:49295363-49295363 2:49068224-49068224
12 FSHR NM_000145.3(FSHR): c.-58T> C single nucleotide variant Uncertain significance rs886056153 2:49381614-49381614 2:49154475-49154475
13 FSHR NM_000145.3(FSHR): c.1596G> A (p.Met532Ile) single nucleotide variant Uncertain significance rs757909841 2:49190364-49190364 2:48963225-48963225
14 FSHR NM_000145.3(FSHR): c.1030G> C (p.Val344Leu) single nucleotide variant Uncertain significance rs772756688 2:49190930-49190930 2:48963791-48963791
15 FSHR NM_000145.3(FSHR): c.947A> G (p.Glu316Gly) single nucleotide variant Uncertain significance rs886056150 2:49191013-49191013 2:48963874-48963874
16 FSHR NM_000145.3(FSHR): c.1330G> A (p.Ala444Thr) single nucleotide variant Uncertain significance rs202162496 2:49190630-49190630 2:48963491-48963491
17 FSHR NM_000145.3(FSHR): c.685A> G (p.Arg229Gly) single nucleotide variant Uncertain significance rs201122960 2:49196006-49196006 2:48968867-48968867
18 FSHR NM_000145.3(FSHR): c.225-11T> C single nucleotide variant Uncertain significance rs886056152 2:49247310-49247310 2:49020171-49020171
19 FSHR NM_000145.3(FSHR): c.603C> T (p.Ser201=) single nucleotide variant Likely benign rs75552966 2:49210116-49210116 2:48982977-48982977
20 FSHR NM_000145.3(FSHR): c.485G> A (p.Arg162Lys) single nucleotide variant Likely benign rs111883853 2:49216155-49216155 2:48989016-48989016
21 FSHR NM_000145.3(FSHR): c.786C> T (p.Val262=) single nucleotide variant Likely benign rs150863050 2:49195905-49195905 2:48968766-48968766
22 FSHR NM_000145.3(FSHR): c.*246T> A single nucleotide variant Likely benign rs72825259 2:49189626-49189626 2:48962487-48962487
23 FSHR NM_000145.3(FSHR): c.*111T> C single nucleotide variant Likely benign rs140106399 2:49189761-49189761 2:48962622-48962622
24 FSHR NM_000145.3(FSHR): c.*563T> C single nucleotide variant Likely benign rs80295823 2:49189309-49189309 2:48962170-48962170
25 FSHR NM_000145.3(FSHR): c.446+10T> C single nucleotide variant Likely benign rs200504733 2:49217695-49217695 2:48990556-48990556
26 FSHR NM_000145.3(FSHR): c.-114T> C single nucleotide variant Likely benign rs115357990 2:49381670-49381670 2:49154531-49154531
27 FSHR NM_000145.3(FSHR): c.24G> T (p.Leu8Phe) single nucleotide variant Likely benign rs115030945 2:49381533-49381533 2:49154394-49154394
28 FSHR NM_000145.3(FSHR): c.*256C> T single nucleotide variant Likely benign rs72873077 2:49189616-49189616 2:48962477-48962477
29 FSHR NM_000145.3(FSHR): c.919G> A (p.Ala307Thr) single nucleotide variant Benign rs6165 2:49191041-49191041 2:48963902-48963902
30 FSHR NM_000145.3(FSHR): c.2039G> A (p.Ser680Asn) single nucleotide variant Benign rs6166 2:49189921-49189921 2:48962782-48962782
31 FSHR NM_000145.3(FSHR): c.-29G> A single nucleotide variant Benign rs1394205 2:49381585-49381585 2:49154446-49154446

UniProtKB/Swiss-Prot genetic disease variations for Ovarian Hyperstimulation Syndrome:

# Symbol AA change Variation ID SNP ID
1 FSHR p.Thr449Ile VAR_017244 rs28928870
2 FSHR p.Asp567Asn VAR_017245 rs28928871
3 FSHR p.Ser128Tyr VAR_039279 rs121909665
4 FSHR p.Thr449Ala VAR_039282
5 FSHR p.Ile545Thr VAR_039284
6 FSHR p.Met512Ile VAR_074535
7 FSHR p.Val514Ala VAR_074536
8 FSHR p.Ala575Val VAR_074537

Expression for Ovarian Hyperstimulation Syndrome

Search GEO for disease gene expression data for Ovarian Hyperstimulation Syndrome.

Pathways for Ovarian Hyperstimulation Syndrome

Pathways related to Ovarian Hyperstimulation Syndrome according to KEGG:

# Name Kegg Source Accession
1 Neuroactive ligand-receptor interaction hsa04080

Pathways related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
5 11.83 VEGFA KDR CDH5
Show member pathways
Show member pathways
10 11.53 REN KDR CDH5
12 10.94 LHCGR FSHR CYP19A1
13 10.92 VEGFA KDR
14 10.89 FSHR FSHB
15 10.89 FSHR FSHB CYP19A1 CGA

GO Terms for Ovarian Hyperstimulation Syndrome

Cellular components related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 VEGFA REN GNRH1 FSHB F5 CGA
2 platelet alpha granule lumen GO:0031093 9.43 VEGFA F5 ALB
3 extracellular region GO:0005576 9.28 VEGFA REN KDR GNRH1 FSHB F5
4 follicle-stimulating hormone complex GO:0016914 8.96 FSHB CGA

Biological processes related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of angiogenesis GO:0045766 9.76 VEGFA KDR CDH5
2 positive regulation of cell migration GO:0030335 9.76 VEGFA KDR FSHB CGA
3 platelet degranulation GO:0002576 9.71 VEGFA F5 ALB
4 male gonad development GO:0008584 9.67 REN LHCGR FSHR
5 activation of adenylate cyclase activity GO:0007190 9.61 LHCGR FSHR
6 positive regulation of focal adhesion assembly GO:0051894 9.6 VEGFA KDR
7 female gonad development GO:0008585 9.59 FSHR CYP19A1
8 cell migration involved in sprouting angiogenesis GO:0002042 9.58 VEGFA KDR
9 peptide hormone processing GO:0016486 9.57 FSHB CGA
10 female gamete generation GO:0007292 9.56 FSHR FSHB
11 uterus development GO:0060065 9.55 FSHR CYP19A1
12 vascular endothelial growth factor signaling pathway GO:0038084 9.52 VEGFA KDR
13 regulation of osteoclast differentiation GO:0045670 9.51 FSHR FSHB
14 positive regulation of positive chemotaxis GO:0050927 9.48 VEGFA KDR
15 Sertoli cell proliferation GO:0060011 9.43 FSHR FSHB
16 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.4 VEGFA KDR
17 ovulation cycle process GO:0022602 9.37 LHCGR FSHR
18 regulation of signaling receptor activity GO:0010469 9.32 FSHB CGA
19 follicle-stimulating hormone signaling pathway GO:0042699 9.26 FSHR FSHB
20 positive regulation of steroid biosynthetic process GO:0010893 9.16 FSHB CGA
21 gonad development GO:0008406 9.13 FSHR CGA AMH
22 hormone-mediated signaling pathway GO:0009755 8.92 REN LHCGR FSHR FSHB

Molecular functions related to Ovarian Hyperstimulation Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-hormone receptor activity GO:0016500 9.16 LHCGR FSHR
2 follicle-stimulating hormone activity GO:0016913 8.96 FSHB CGA
3 hormone activity GO:0005179 8.92 GNRH1 FSHB CGA AMH

Sources for Ovarian Hyperstimulation Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....